Immunovant/$IMVT
1D1W1MYTD1Y5YMAX
Capital at risk
About Immunovant
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
- Ticker
- $IMVT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 315
- Headquarters
- Durham, United States
- Website
- immunovant.com
Immunovant Metrics
BasicAdvanced
$7.5B
-
-$2.82
0.81
-
Price and volume
Market cap
$7.5B
Beta
0.81
52-week high
$45.42
52-week low
$14.58
Average daily volume
1.2M
Financial strength
Current ratio
7.269
Quick ratio
6.819
Profitability
EBITDA (TTM)
-565.607
Effective tax rate (TTM)
0.13%
Management effectiveness
Return on assets (TTM)
-46.73%
Return on equity (TTM)
-80.10%
Valuation
Price to book
10.2
Price to tangible book (TTM)
10.2
Price to free cash flow (TTM)
-16.779
Free cash flow yield (TTM)
-5.96%
Free cash flow per share (TTM)
-2.168
Growth
Earnings per share change (TTM)
-0.66%
3-year earnings per share growth (CAGR)
13.39%
What the Analysts think about Immunovant
Analyst ratings (Buy, Hold, Sell) for Immunovant stock.
Analyst projections of the future price of Immunovant stock.
Bulls say / Bears say
IMVT-1402 showed strong Week 16 response rates of 72.7% ACR20 and 54.5% ACR50 in an open-label difficult-to-treat rheumatoid arthritis trial, supporting its potential differentiated efficacy profile (Reuters)
As of June 30, 2026, Immunovant held $797.8 million in cash and cash equivalents, providing sufficient runway to support the commercial launch of IMVT-1402 in Graves’ disease under current operating plans (SEC 8-K)
Analysts maintain a consensus 'buy' rating with a median 12-month price target of $42.00, implying roughly 60% upside from May 2026 levels (Reuters)
Q4 FY2026 net loss widened to $147.86 million from $106.45 million a year earlier, driven by a 51.9% increase in R&D spending, highlighting continued high cash burn before any product revenue (Reuters)
Batoclimab failed to meet primary endpoints in two Phase 3 thyroid eye disease trials, leading to program discontinuation and raising concerns about pipeline execution risk (Reuters)
Milestone payments mandated by the HanAll license for IMVT-1402 development could require significant cash expenditures upon trial progression, potentially straining Immunovant's financial flexibility (Form 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2026.
Immunovant Financial Performance
Revenues and expenses
Immunovant Earnings Performance
Company profitability
Upcoming events
No upcoming events
Immunovant News
AllArticlesVideos
Funds containing Immunovant
AllUSDGBPEUR
Fund name | Fund size | $IMVT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.51% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.51% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.11% |
iShares MSCI World Small Cap$WSML | $9B | 0.03% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.